
    
      Two doses of ASP3550 were administered to patients with prostate cancer. The primary efficacy
      variable was the effect of ASP3550 on the maintenance of serum testosterone suppression. In
      addition, the safety and pharmacokinetics of ASP3550 will be investigated.
    
  